

Supplemental Information

SUPPLEMENTAL TABLE 3 Vaccine Coverage at 1 Year

Vaccine	11- to 12-Year-Olds (<i>n</i> = 33 818)					13- to 18-Year-Olds (<i>n</i> = 76 346)				
	Coverage at 1 Year (%)	Coverage Change Over Previous 1 Year (%)	Difference From Control (%) (95% CI)	<i>P</i>		Coverage at 1 Year (%)	Coverage Change Over Previous 1 Year (%)	Difference From Control (%) (95% CI)	<i>P</i>	
Tdap										
Control	90.6	8.1	Ref	—	—	80.6	5.0	Ref	—	—
In-person	91.0	7.9	−0.2	(−1.8 to 1.3)	.74	81.1	4.5	−0.5	(−1.8 to 0.9)	.48
Webinar	93.9	7.5	−0.6	(−2.1 to 0.9)	.43	82.3	4.8	−0.1	(−1.5 to 1.2)	.83
Meningococcal										
Control	63.6	19.7	Ref	—	—	73.8	7.3	Ref	—	—
In-person	66.7	18.5	−1.2	(−5.3 to 3.0)	.58	73.9	7.1	−0.2	(−2.2 to 1.8)	.83
Webinar	65.0	17.8	−1.8	(−5.9 to 2.2)	.37	68.9	7.4	0.1	(−1.9 to 2.1)	.90
HPV (≥1 dose)^a										
Control	41.0	12.0	Ref	—	—	62.3	7.5	Ref	—	—
In-person	33.8	10.2	−1.9	(−4.5 to 0.8)	.17	63.4	7.5	0.0	(−1.9 to 1.8)	.98
Webinar	37.0	11.1	−0.9	(−3.5 to 1.6)	.47	60.8	6.4	−1.1	(−3.0 to 0.7)	.22
HPV (3 doses)^a										
Control	16.8	4.9	Ref	—	—	38.6	5.3	Ref	—	—
In-person	14.8	4.2	−0.7	(−2.1 to 0.6)	.29	42.6	5.0	−0.3	(−1.4 to 0.9)	.62
Webinar	16.3	5.1	0.2	(−1.2 to 1.6)	.78	41.8	4.6	−0.7	(−1.8 to 0.5)	.26
MMR (2 doses)										
Control	83.6	0.1	Ref	—	—	80.4	0.2	Ref	—	—
In-person	82.6	0.1	0.0 ^b	—	—	77.5	0.2	−0.1 ^b	—	—
Webinar	87.7	0.1	0.0 ^b	—	—	82.7	0.2	0.0 ^b	—	—
HBV (3 doses)										
Control	88.1	0.1	Ref	—	—	83.4	0.2	Ref	—	—
In-person	86.1	0.1	0.1 ^b	—	—	80.1	0.2	0.0 ^b	—	—
Webinar	91.1	0.1	0.1 ^b	—	—	84.2	0.2	0.1 ^b	—	—
Varicella (2 doses)										
Control	68.9	3.9	Ref	—	—	53.1	2.4	Ref	—	—
In-person	67.1	3.0	−1.0	(−2.4 to 0.5)	.19	49.7	2.0	−0.4	(−1.2 to 0.4)	.35
Webinar	70.0	4.4	0.5	(−1.0 to 2.0)	.50	42.3	2.7	0.2	(−0.6 to 1.1)	.58

Intervention arms had different coverage changes only for varicella vaccination among 11- to 12-year-olds (1.5% [95% CI: 0.0 to 2.9]). Vaccine coverage was unadjusted. Vaccine coverage change and difference from the control arm were adjusted for publicly funded vaccine doses and account for clustering according to clinic. Dashes (—) indicate empty cells related to reference categories or suppressed data.

^a HPV vaccine coverage assessed only for female 11- to 12-year-olds (*n* = 15 554) and 13- to 18-year-olds (*n* = 36 200).

^b CIs and *P* values for difference estimates suppressed due to small cell sizes.